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SUMMARY
The newly revised 2021 ISSCR Guidelines for Stem Cell Research and
Clinical Translation includes scientific and ethical guidance for the
transfer of human pluripotent stem cells and their direct derivatives into animal models. In this white paper, the ISSCR subcommittee that drafted these guidelines for research involving the
use of nonhuman embryos and postnatal animals explains and
summarizes their recommendations.

The newly revised ISSCR Guidelines for Stem Cell Research
and Clinical Translation includes scientific and ethical guidance for the transfer of human pluripotent stem cells and
their direct derivatives into animal models (ISSCR, 2021).
We are the members of the International Society for Stem
Cell Research (ISSCR) Task Force subcommittee that drafted
these guidelines for stem cell research involving the use of
nonhuman embryos and animals, and we summarize and
explain our recommendations in this white paper. This
report should be read in conjunction with Section 2 of
the guidelines, entitled ‘‘Laboratory-Based Human Embryonic Stem Cell Research, Embryo Research, and Related
Research Activities,’’ and Appendix 1.
As noted in the beginning of the 2021 ISSCR guidelines:
‘‘The primary societal mission of basic biomedical research
and its clinical translation is to alleviate and prevent human suffering caused by illness and injury.’’ To fulfill this
mission, stem cell scientists, geneticists, developmental bi-

ologists, preclinical investigators, and others endeavor to
understand basic human stem cell biology and differentiation potential and to generate compelling new animal
models for understanding human disorders. Of equal
importance, collective efforts are aimed to explore the
safety and efficacy of new stem cell-based treatment modalities in laboratory animals prior to initiation of clinical trials. Together, these aims make research involving the transfer of human stem cells and their direct derivatives into
animal hosts necessary for stem cell science to progress to
clinical applications. While recognizing that some people
have concerns about this research, the potential value of
these scientific efforts led our subcommittee to consider
not whether animal models ought to be used, but rather
how and under what circumstances such research could
be permissible.
To explain the scope of our recommendations, our subcommittee drafted our guidelines for stem cell-based animal research with three boundaries in mind.
The first is the legal boundary. Our recommendations
were written in general terms so that they could be used
by different institutions internationally with potentially
differing local research restrictions. Investigators should
use our guidelines while exercising appropriate judgment
in individual cases and in consultation with research policy
experts to ensure they are conforming to local and national
laws, first and foremost.
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The second boundary is the current scientific boundary.
While there has been much learned from the use of animal hosts in stem cell research, more hard work remains,
in particular the challenge of learning how to enable human cells to survive longer and to integrate more extensively in animal hosts. For years, public concerns have existed over the possibility of generating mixed human/
nonhuman research animals through stem cell technology (Greene et al., 2005), especially within the central
nervous system (CNS) of large animal hosts like
nonhuman primates (NHPs). However, the simple truth
is that the most anxiety-provoking scenarios—e.g., the
generation of laboratory animals with human-like cognitive traits—are currently scientifically out of reach and/
or might even fail to meet the professional standards for
review we advocate in our guidelines. Given the reality
of current technical limitations, our goals were (1) to offer
research guidelines that are calibrated to what may be
scientifically possible in the near future and (2) to help
research proceed responsibly in an incremental fashion.
Thus, our guidelines for the transfer of human stem cells
and their direct derivatives into animal hosts are intended
to provide guidance over the next 5–10 years. Our subcommittee did not want merely imaginable scenarios surrounding stem cell-based animal research to dictate
what the professional standards ought to be for research
conduct and oversight, especially before there was good
scientific evidence to support imagined concerns. The incremental approach we advocate in our recommendations
would allow researchers to obtain new scientific data and
for the ISSCR to evaluate such data and revise future professional guidelines accordingly.
The third boundary we considered is the boundary between prior regulatory experience with animal research
oversight more generally and the novel aspects of stem
cell-based research involving animal hosts. It is important
to acknowledge that there are many well-articulated, institutionally embedded standards and regulations around the
world for the use of animals in biomedical research. Stem
cell research involving the use of animal hosts should be
seen as part of these widely accepted animal research standards and, if necessary, should build upon these standards
in practicable ways. Only when existing animal research
standards are insufficient to capture unique aspects of
stem cell science should additional guidelines be necessary.
It is in the spirit of avoiding stem cell exceptionalism in the
oversight of animal research that our subcommittee provides our recommendations. Indeed, the boundary between accepted practices in animal research and oversight
on the one hand and new forms of stem cell research on the
other is far less substantial than some may suppose, given
the current state of the science. Therefore, our recommendations for stem cell research involving animal hosts will
1410 Stem Cell Reports j Vol. 16 j 1409–1415 j June 8, 2021

seem familiar to biomedical researchers with experience
in animal studies, as they should.
Both the 2021 ISSCR guidelines and this white paper are
divided along two broad forms of stem cell research
involving animals: (1) research involving the transfer of human pluripotent stem cells or their direct derivatives into
nonhuman animal embryos and prenatal animals and (2)
the transfer of human stem cells or their direct derivatives
into postnatal animals. We begin with nonhuman embryo
studies, followed by the use of postnatal animals, since these
two forms of research involve different issues and oversight
mechanisms, which deserve to be considered separately.
Guidelines for stem cell research using nonhuman
embryos and prenatal animals
The 2021 ISSCR guidelines state that research involving the
transfer of pluripotent human stem cells into nonhuman animal embryos may fall under different categories of review by
a specialized research oversight process—what was previously called the EMRO process in the 2016 ISSCR guidelines
(more information regarding each of these research categories is available in Clark et al. 2021, this issue). Just as there
have been decades of regulatory experience around the
world for animal research, stem cell research oversight has
propagated globally and operated effectively since the early
2000s. Furthermore, human embryo research oversight has
been successfully administered in the United Kingdom and
many other locales for decades, long before the advent of human pluripotent stem cell research. Therefore, the categories
of review published in the new ISSCR guidelines are not
entirely new, but rather build upon these two types of
research oversight experience. Given the fact that traditional
animal research committees do not review animal embryo
protocols per se, beyond ascertaining the welfare of any
gestational surrogates or animal gamete donors used, our
subcommittee believed it was appropriate for stem cell
research involving animals and animal embryos to be incorporated into the following category system for embryo
research proposed by the ISSCR. Here are the various categories of research presented in the 2021 guidelines, which
together call for different levels of oversight:
Category 1A: research that is exempt from a specialized
scientific and ethics oversight process after being assessed
by the appropriate existing mandates and committees for
laboratory research.
Category 1B: research that is reportable to the entity or
body responsible for the specialized scientific and ethics
oversight process, but not normally subject to further or
ongoing review, at the discretion of the entity responsible
for the oversight process and subject to regulations and policies in the jurisdiction.
Category 2: forms of research with embryos, certain chimeras, and stem cell-based embryo models that are
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permissible only after review and approval through a
specialized scientific and ethics review process.
Category 3A: prohibited research due to unresolved safety
and ethics concerns.
Category 3B: prohibited research due to broad international consensus that such experiments lack a compelling
scientific rationale and are widely considered to be
unethical.
Depending on specific protocol details, stem cell research
involving the use of nonhuman animals and embryos
could span across any one of these categories.
Falling under category 1A is the transfer of human stem
cells, their derivatives, or other human cells into postnatal
animal hosts. Importantly, while this form of research is
not relevant for specialized scientific and ethics review for
embryo research, our subcommittee recommends that this
type of work be reviewed by normal institutional animal
research committees supplemented with stem cell-specific
expertise in certain cases, as we explain in the subsequent
section of this report entitled ‘‘guidelines for stem cell
research using postnatal animals.’’
Falling under category 1B is research in which human
pluripotent stem cells are transferred into nonhuman
mammalian embryos and cultured in vitro for the minimum time necessary to achieve the scientific objective
without gestation. We contend that animal embryos
containing transferred human cells are not themselves
human embryos. For this reason, they are not ethically
equivalent to in vitro fertilization-derived human embryos maintained in culture and permitted for research
use. To date, studies involving so-called ‘‘chimeric embryo’’ cultures have yet to show a significant human
contribution to host animal embryos (Tan et al., 2021).
Nevertheless, researchers are encouraged to report their
planned in vitro experiments to their committee or
body responsible for the specialized scientific and ethics
oversight process to help identify cases that may warrant
full review. To this end, scientists pursuing human-tononhuman chimeric in vitro embryo research (without
gestation in animal surrogates) should consult with institutional review committees or the body responsible for
the specialized scientific and ethics review process to
ensure that their proposed research does not require
specialized review and approval.
Falling under category 2 is research in which human
pluripotent stem cells or their derivatives with broad potential are introduced into (1) a nonhuman embryo or fetus
in utero or (2) a nonhuman embryo in vitro followed by
transfer into a nonhuman uterus. Such experiments—if
they are scientifically justified for the use of NHPs above
all other laboratory species—must exclude great and lesser
ape species hosts (i.e., chimpanzees, gorillas, orangutans,
bonobos, gibbons, and siamangs), as apes are prohibited

from being used for invasive research in most parts of the
world.
This form of chimeric embryo research is permissible
only after it has been reviewed through a process of specialized scientific and ethics review. Unlike in vitro studies, the
developmental potential of chimeric embryos might be
significantly greater if they are gestated for a period of
time in a nonhuman uterus, since at our current level of
technology, in vitro culture conditions are not as permissive
as the natural uterine environment for advanced maturation. Due to the possibility of greater degrees of human
cell integration and development within animal host embryos or fetuses, the gestation of chimeric embryos thus
warrants close scientific and ethical review. This review
should take into account the following points:
1. Any proposed chimeric embryo study involving uterine transfer or gestation must have a compelling scientific rationale and necessitate the use of these approaches rather than alternative models, while also
using the minimum number of chimeric embryos
necessary to achieve the scientific objective.
2. Researchers must justify why a particular species of
host embryo is necessary. We recommend that scientific studies of chimeric embryo gestation are potentially permissible and thus require review for all laboratory animal species and NHP host species, except
great apes and lesser apes (i.e., except chimpanzees,
gorillas, orangutans, bonobos, gibbons, and siamangs). We explicitly exclude the use of great and
lesser apes, first because the procedures necessary to
derive oocytes for in vitro host embryo creation
and/or to remove chimeric embryos from ape surrogates are themselves impermissibly invasive for these
species. It is a commonplace research restriction that
apes cannot be used for invasive biomedical research
(Institute of Medicine, 2011). Second, the use of great
and lesser apes for chimeric embryo research purposes could cross into the ISSCR’s impermissible categories of research as defined by categories 3A and 3B,
especially in light of the fact that other alternatives—
notably, NHP species that are more evolutionarily
distant from humans—are available and routinely
used for similarly invasive studies in reproductive
medicine.
3. The length of chimeric embryo gestation must be
scientifically well justified and minimally necessary
to achieve the scientific aim. Investigators must proceed step by step, stopping at well-defined incremental time points to assess the degree and scope of
chimerism during development before going all the
way to full gestation (if full gestation is among the
well-justified goals of the research).
Stem Cell Reports j Vol. 16 j 1409–1415 j June 8, 2021 1411
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4. To avoid uncontrolled and widespread chimerism, researchers should endeavor to target chimerism to a
particular organ system or region of the gestating
chimeric animal (Kobayashi et al., 2015; Hashimoto
et al., 2019). Techniques such as blastocyst complementation—whereby a specific cell type or organ is
effectively deleted as the host embryo develops and
replaced by engrafted pluripotent human stem cells
or their derivatives—can lead to a specific organ being replaced entirely by derivatives from the donorderived stem cells. By itself this targeted chimerism
may not prevent contributions elsewhere in the
chimera, thus the need for an incremental approach.
Nonetheless, if the host cells have an advantage over
the donor cells, such as even a slightly faster rate of
cell replication, then the donor cells will be disadvantaged and effectively selected against, leading to little
or no contribution outside the organ of choice.
5. For targeted chimeric embryo studies that aim to chimerize the CNS of the host species and then permit
full gestation and live birth, we refer decision-makers
to our subsection below dealing with the chimerism
of postnatal animals.
Finally, our subcommittee placed under category 3B (i.e.,
that which lacks compelling scientific rationale and is
widely considered to be unethical) any research involving
(1) the transfer of chimeric embryos mixing animal and human cells—whether predominantly animal or human—to
the uterus of a human or great or lesser ape and (2) the
breeding of animal chimeras incorporating human cells
with the potential to form human gametes. We suggest
that research that might result in the presence of human
gametes and their precursors in the gonads of laboratory
animals is not of significant ethical concern per se, as
long as the animals are not allowed to breed.
Guidelines for stem cell research using postnatal
animals
In addition to endorsing the categories of scientific and
ethics review outlined above, our subcommittee determined that nonembryonic studies involving the transfer
of human stem cells or their direct derivatives into postnatal animals should continue to be reviewed by the usual
animal research committees utilized by research institutions. Research involving animals should also comply
with the principles of the 3Rs (replacement, reduction,
and refinement; see www.nc3rs.org.uk) and follow the
‘‘ARRIVE guidelines’’ (Percie du Sert et al., 2020).
That said, our subcommittee strongly recommends that
research involving the transfer of human stem cells or their
direct neural and/or glial derivatives into the CNS of animal hosts requires review by animal research oversight
1412 Stem Cell Reports j Vol. 16 j 1409–1415 j June 8, 2021

committees supplemented by reviewer expertise in stem
cell or developmental biology (ISSCR, 2006; Hyun et al.,
2007; Academy of Medical Sciences, 2011). This call for
stem cell-specific review by an institutional animal
research committee is justified by the novelty of modifying
research animals in this manner. The potential CNS effects
of human stem cells and their derivatives on postnatal animals have yet to be fully ascertained, due to a general lack
of experience in this area of stem cell science. Furthermore,
research aimed at integrating human neural cells into the
brains of laboratory animals has raised concerns about
the moral status of animals resulting from such humanto-animal stem cell transplantation research (Greely,
2021; Wu et al., 2016).
Some in our subcommittee believe these concerns run
too far ahead of the actual science, and erroneously
conflate higher degrees of biological structural humanization with greater moral humanization, the latter
comprising unique human-like cognitive capacities, such
as the emergence of higher-order intellectual processing capabilities and thought, and self-consciousness. But such
complex mental traits are not biologically assured even in
infant brains that are 100% human, absent the experience
of social and nurturing conditions of child-rearing over a
time span of years (Hyun, 2016). Furthermore, the behavioral repertoires of chimeras will necessarily be narrower
still for biological reasons. Even in cases in which the
contribution of human cells to the CNS in a laboratory animal is extensive, in addition to fundamental differences in
size and early regional patterning from the host embryo,
the primary sensory and motor output systems will be
host derived. Nevertheless, in light of potential concerns
around the possibility of significant or meaningful
enhancement of animal cognition by human cells—to a
degree that some might find disconcerting or of frank
ethical concern—our subcommittee has provided the
following research guidelines for investigators and regulators dealing with stem cell protocols that might alter animals’ neurological functions. This approach tries to avoid
giving undue influence to unsupported, imagined possibilities and strives to be grounded in observable behaviors and
reasonable inferences.
We recommend that supplemented animal research
oversight in this area should build upon common review
standards with an emphasis on animal welfare. As with
all modified animal models used in bioscience, reviewers
should weigh the potential benefits of the research and,
in particular, the potential clinical implications and benefits thereof. Reviewers should utilize available baseline
nonhuman animal data grounded in rigorous scientific
knowledge or reasonable inferences, while applying a diligent application of animal welfare principles. Past experiences with genetically altered laboratory animals have
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shown that reasonable caution might be warranted if
changes carry the potential to produce new defects and deficits. Current best practices dictate that research involving
modified animals must involve (1) the establishment of
baseline animal data, (2) ongoing data collection during
research concerning any deviation from the norms of species-typical animals, (3) the use of small pilot studies to
ascertain any welfare changes in modified animals, and
(4) ongoing monitoring and reporting to animal research
oversight committees authorized to decide the need for
real-time changes in protocols and, if necessary, the withdrawal of animal subjects. Additional recommendations
for stem cell-based animal studies of the CNS are as follows.
These track closely to the ISSCR Ethics and Public Policy
Committee white paper on this topic when the ISSCR first
released stem cell research guidelines in 2006 (Hyun et al.,
2007):
1. Additional data collection and monitoring by animal
research committees should be commensurate with
the anticipated characteristics of the modified animal
in the context of the proposed research. Issues
regarding the possible change in or enhancement
of an animal’s behavior or operationally assessed
cognition should be addressed through diligent
application of accepted principles for the humane
treatment and protection of animals in research;
these should proceed through regular animal
research oversight mechanisms.
2. Monitoring and data collection should be based
upon a sound assessment of the developmental trajectories of the animal host that may be further
affected by taking into account the environmental
and epigenetic context in which the donor genes or
cells are going to be deployed. It should be grounded
in existing knowledge of such trajectories, with
reasonable scientific inferences as to their phenotypic and fate potential, with thorough reference to
the physiological and behavioral tests and assessments currently available by which to assess the
host species.
3. Research involving the modification of the CNS, as
established with the introduction of human stem
cells or their neural and/or glial derivatives in a way
that they contribute to the brains or spinal cords of
animal hosts, may attempt to model or directly
mimic aspects of human neurological and neuropsychiatric function. As such, this research may demand
specialized cognitive and behavioral assessments of
the sort conducted in neuroscientific research. There
may be an irreducible degree of uncertainty about the
internal cognitive processes of any new animal
model, in particular how it would manifest distress,

anxiety, or other aspects of animal welfare. In such
cases, as with transgenic animals, researchers and institutions should familiarize themselves with available options for behavioral response assessment.
A baseline of normal behavioral data for the test species and strain should be available before experimentation is permitted, so as to enable clear and rapid
identification of behavioral differences or abnormalities associated with treatment and/or human cell
transfer. Investigators and institutions should also
consider requiring limited pilot studies to produce
initial data on the effects of experimental interventions on modified animals, monitoring all deviations
from normal behaviors, with prescribed discussion
with pertinent animal welfare committees before
proceeding to definitive experiments.
4. Investigators and institutions should also make
appropriate adjustments to research protocols to
take into account new data or unanticipated responses from animal subjects that may inform or
alter the continued permissibility of the animal’s
participation in the study. These include identifying
any novel signals suggesting a material change
in an animal’s condition, comfort, or behavioral
state or repertoire, whether by way of deterioration
or enhancement. Regular reassessment of animal
welfare during the course of experimentation is
essential.
5. Research with a known, intended, or well-grounded
significant potential to create some aspect suggestive
of human cognition, self-awareness, behavior or
behavioral pathology, while not prohibited, should
be subject to close scrutiny, taking care to ensure
the humane protection of animal subjects. Such
studies require a clear and compelling justification,
grounded in the potential for significant scientific
breakthrough, clinical advance, or both.
6. Through retained advisors or committee diversity,
animal research review committees should ensure
that they have sufficient scientific and clinical expertise to make appropriate judgments concerning the
matters discussed in these recommendations.
In addition to endorsing and updating these key recommendations from the 2007 ISSCR Ethics and Public Policy
Committee white paper, our subcommittee also drafted
additional recommendations to help stem cell investigators and oversight committee members who may be working with large animal studies for the first time. In these
cases, investigators using large and often complex animal
models, such as NHPs and livestock, should follow international standards for NHP and livestock animal research,
which call for frequent monitoring of animals whenever
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there is the potential for unexpected outcomes and unanticipated phenotypes.
With regard to stem cell studies involving NHP host species (excluding, as mentioned above, the great and lesser
apes), we strongly recommend that stem cell investigators
familiarize themselves with the unique challenges posed
by working with NHPs. First, we cover some common practical issues, followed by issues that are pertinent for stem
cell studies of the CNS in postnatal NHPs.
Keeping NHPs in the laboratory creates a number of
problems that are not shared with other commonly used
laboratory mammals. Unlike domesticated species, NHPs
are potentially aggressive wild animals and are highly reactive to any unfamiliar stimuli. In addition to posing a bite
and scratch hazard, NHPs can be challenging and difficult
to handle safely because they possess great strength, dexterity, and intelligence.
Because of the many physical and behavioral characteristics of NHP species and the many factors to consider when
using these animals in a biomedical research setting,
personnel competent in the behavior of each species of
NHP should be available for advice, and species-specific
plans for housing and management should be developed.
For animal care staff and scientists working with NHPs,
training should include species-specific information such
as unique biological and behavioral requirements, environmental enrichment, methods used for the introduction
and removal of animals, and social dynamics.
It is crucially important to take seriously these and other
factors that could have an impact on the well-being and
behavior of NHPs used in neurological stem cell studies.
Failure to do so not only could lead to the unnecessary
and wrongful suffering of NHPs, but also could confuse
monitors’ assessments of whether an investigational stem
cell-based intervention is itself causing observable effects
on the animals’ behavior that should inform future
research. This point is overlooked in the stem cell ethics
literature. As a case in point, the ethical discourse around
stem cell-based neurological chimerism thus far has not
taken into account the potential impact of practical issues
such as animal housing.
Housing NHPs in social groups best replicates the social
interactions they experience in the wild and thereby promotes species-typical behaviors and psychological well-being (Tardif et al., 2013). For some NHP species, temporary
removal of an individual from its social group may cause
it acute stress, and permanent removal may cause distress
(the inability to cope with stress). Because of this variability, investigators and veterinarian staff must be aware
of normal behaviors of individual NHPs and must know
how to identify potential signs of stress and distress. Any
singly housed modified NHPs should be kept so for the
minimum length of time required. The need for single
1414 Stem Cell Reports j Vol. 16 j 1409–1415 j June 8, 2021

housing should be reviewed by animal research committee
members and veterinary staff. Because NHPs are social animals, single housing can produce a reduced range of species-typical behavior, increased environmental stressors,
and self-inflicted wounding or withdrawn behavior. Not
only could these outcomes affect the welfare of modified
NHPs, but they might also confound investigators’ and regulators’ judgments about any potential behavioral changes
caused by the transplantation per se of human stem cells or
their direct derivatives.
Within the next 5–10 years, some investigations from
stem cell scientists may be directed to generate transplantable human organs in livestock animals. To help prepare investigators and their regulators for this possibility well in
advance, our subcommittee recommends familiarity with
the following issues and best practices so that stem cell protocols can be designed appropriately.
First, the use of agricultural animals in research is subject
to the same ethical considerations as for other animals in
research. Regardless of the category of research (agricultural
or biomedical), institutions are expected to provide oversight of all research animals and ensure that pain and
distress are minimized.
Second, the study parameter, rather than the category of
research, should determine the setting (farm or laboratory).
Management systems for all farm animals should accommodate their natural behaviors, such as the need to graze,
forage, and exercise. For animals maintained in a farm
setting, the Guide for the Care and Use of Agricultural Animals
in Research and Teaching is a useful resource (Federation of
Animal Science Societies, 2010).
Third, most agricultural animals are social species, and
attention to conditions and space needs that allows appropriate social interaction to occur is imperative (Edwards
et al., 2018).
Fourth, personnel (animal care, veterinary, and researchers) should have experience working with livestock.
The use of positive reinforcement techniques for acclimatization of these larger species to handling and researchrelated procedures contributes to the safety of personnel
and of the animal subjects.
Finally, veterinarians should be knowledgeable about the
health status of the species on study. Unlike most traditional laboratory animal species, biosecurity is not consistent among sources for livestock animals. Commercial suppliers of laboratory animals and land grant institutions
generally maintain herds with known disease status.
Conversely, disease status and health records may not be
readily available for animals obtained from smaller farms
or producers. Prepurchase review of animal health records
and appropriate quarantine procedures can assist in preventing the introduction of species-specific and zoonotic
pathogens.
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Conclusion
Stem cell-based animal research continues to be an active
area of stem cell and translational science. The recommendations in the 2021 ISSCR guidelines discussed in this
report aim to promote the responsible advance of these activities. Much of what is in this report is neither strikingly
new nor flashy from the standpoint of research ethics,
despite the fact that animals with some human composition or elements have long been in the public imagination.
This last point reinforces the need for stem cell researchers
to avoid communicating about their chimera research projects with the public in misleading or inaccurate ways.
While we are aware that some individuals would prefer to
prohibit this research outright, we proceed from the position that under the correct conditions and with appropriate oversight, this research can provide valuable knowledge and so can ethically be undertaken. Thus, our
recommendations are intended to help our audience—researchers and regulators—navigate and move forward
with designing, conducting, and overseeing stem cell
research protocols involving the use of animal hosts. These
coordinated efforts should be seen as part of a much
broader constellation of animal and human embryo
research that has driven broad advances in biomedicine
of the past several decades. We see no need to reinvent
the wheel of research ethics when considering the transfer
of human stem cells and their derivatives into animal
models—rather, the addition of a few stem cell-specific
spokes as needed should be sufficient.
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